Innovent Biologics broadens the scope of its Phase 3 MarsLight-11 study, targeting a wider patient population for its IBI363/TAK-928 oncology candidate to strengthen its market position.
Expansion of the Phase 3 MarsLight-11 study to include non-squamous NSCLC patients broadens the potential market for IBI363/TAK-928, supporting a positive outlook for Innovent.
Innovent Biologics has announced the expansion of its Phase 3 MarsLight-11 clinical trial to include patients with non-squamous non-small cell lung cancer (NSCLC). This strategic move broadens the potential market reach for the company's IBI363/TAK-928 candidate, signaling a significant step forward in its oncology pipeline development.
The expansion allows Innovent to evaluate the efficacy of IBI363/TAK-928 in non-squamous NSCLC patients, potentially broadening the drug's future clinical application and market opportunity.